SIGNUM BIOSCIENCES

Basic Information

7 DEER PARK DR, STE H
MONMOUTH JUNCTION, NJ, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 144196354
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. A Topical Non-steroidal Anti-inflammatory for Atopic Dermatitis

    Amount: $1,675,030.00

    DESCRIPTION (provided by applicant): Atopic dermatitis is a chronic dermatological condition afflicting mostly infants and young children. Current treatments are associated with a wide range of side e ...

    SBIR Phase II 2013 Department of Health and Human Services
  2. A Topical Non Steroidal Anti-inflammatory for Rosacea

    Amount: $2,975,892.00

    DESCRIPTION (provided by applicant): Rosacea is a chronic dermatological condition characterized by flushing, erythema, papules, pustules, inflammatory nodules and telangiectasia. Although disease eti ...

    SBIR Phase II 2011 Department of Health and Human Services
  3. A Novel Class of Therapeutic Agents for the Treatment of Skin Diseases Associated

    Amount: $356,919.00

    DESCRIPTION (provided by applicant): N-acetyl-S-famesyl-L-cysteine (AFC) and its derivatives (isoprenylcysteine (IPC) analogs) represent a novel class of topically absorbed NSAIDs whose activity is re ...

    SBIR Phase I 2010 Department of Health and Human Services
  4. A Novel Class of Topical Pleitropic Anti-Acne Therapeutics

    Amount: $327,178.00

    DESCRIPTION (provided by applicant): Acne is a multifactorial disease affecting ~50 million people in the US. Three main factors contribute to the pathogenesis of acne; 1) P. acnes growth 2) P. ac ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. Phosphoprotein phosphatase 2A, a new target for Alzheimer's Disease interventio

    Amount: $324,717.00

    DESCRIPTION (provided by applicant): Abnormal hyperphosphorylation of tau plays an important role in Alzheimer's disease (AD) and other tauopathies. Current therapeutic approaches with focus on tau ki ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. Topical Non-Steroidal Anti-Inflammatories for the Treatment of Rosacea

    Amount: $1,568,460.00

    DESCRIPTION (provided by applicant): Isoprenylcysteine (IPC) analogs modulate heterotrimeric G-protein coupled receptor (GPCR) signaling pathways, representing a novel class of topical anti-inflammato ...

    SBIR Phase II 2009 Department of Health and Human Services
  7. A Novel Class of Non Steroidal Anti-Inflammatories

    Amount: $298,744.00

    DESCRIPTION (provided by applicant): Isoprenylcysteine (IPC) analogs, such as N-acetyl-S-farnesyl-L-cysteine (AFC) modulate heterotrimeric G- protein and Ras-related signaling pathways, representing ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government